Clinical trials: Anxiety Generalized
Generalized Anxiety Disorder, Seroquel XR
Generalized Anxiety and Seroquel
The 12 week clinical trial of Seroquel in Generalized Anxiety Disorder (GAD) patients will be combined with fMRI experiments.
- Trial name
- GAD (NCT01066143)
- Testing
- Seroquel XR
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Generalized Anxiety Disorder
A Comparison Between Cognitive, Behavioral, and Cognitive-Behavioral Therapy for Generalized Anxiety Disorder
This study will evaluate the effectiveness of three adaptive coping treatments in lessening anxiety in adults with generalized anxiety disorder.
- Trial name
- NCT00635999
- Testing
- Applied relaxation and self-control desensitization, Cognitive therapy (CT), Cognitive-Behavioral Therapy
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Michelle G. Newman
Generalized Anxiety Disorder, Panic Disorder
Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder
An 8-week, open-label trial in 848 subjects at 212 sites to compare time to response in symptoms of anxiety in subjects treated with Niravam™ and a newly prescribed Selective Serotonin Reuptake Inhibitor (SSRI)or Serotonin and…
- Trial name
- NCT00266409
- Testing
- Niravam, SSRI/SNRI
- Where
- United States
- Volunteers
- 418 people
- Sponsor
- UCB Pharma
PostTraumatic Stress Disorder
Effectiveness and Acceptability of Stellate Ganglion Block for Posttraumatic Stress Disorder Symptoms - Effectiveness
This is a multisite, randomized, blinded, sham-procedure-controlled study to evaluate the efficacy of right-sided stellate ganglion block (SGB) on the acute symptomatology of Post traumatic Stress Disorder (PTSD), evaluated by…
- Trial name
- NCT03077919
- Testing
- Ropivacaine
- Where
- 3 sites in United States, Germany
- Volunteers
- 113 people
- Sponsor
- RTI International
Depression, Generalized Anxiety Disorder
A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients
For this trial, the investigators propose a prospective trial of a collaborative care program to identify and treat depression, generalized anxiety disorder, and panic disorder among patients admitted to the hospital for an acute…
- Conditions
- Depression, Generalized Anxiety Disorder, Panic Disorder
- Trial name
- MOSAIC (NCT01201967)
- Testing
- Collaborative care, Usual care
- Where
- United States
- Volunteers
- 183 people
- Sponsor
- Massachusetts General Hospital
Cognitive Behavioral Therapy, Autism Spectrum Disorder
Stepped-Care Cognitive-Behavioral Treatment for Youth With ASD and Anxiety
This study implements a parent-led, flexible, individually-tailored cognitive-behavioral intervention for children with ASD and anxiety.
- Conditions
- Cognitive Behavioral Therapy, Autism Spectrum Disorder, Anxiety Disorders, Obsessive-Compulsive Disorder
- Trial name
- NCT03720795
- Testing
- Stepped Care CBT
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Baylor College of Medicine
Generalized Anxiety Disorder
rTMS Pilot for Anxiety
The purpose of this study is to evaluate the safety and tolerability of 1 Hz parietal stimulation in anxiety. Our approach will be to administer 1 week of open-label accelerated 1 Hz parietal rTMS (5 days, 8 sessions/day, 600…
- Trial name
- NCT05306977
- Testing
- Open-label accelerated 1 Hz repetitive transcranial magnetic stimulation
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Pennsylvania
Generalized Anxiety Disorder
Telephone Psychotherapy for Late-Life Generalized Anxiety Disorder (GAD)
The purpose of this study is to determine if cognitive-behavioral therapy (CBT)and supportive therapy delivered by telephone are effective for reducing worry and anxiety in rural older adults with Generalized Anxiety Disorder…
- Trial name
- NCT01259596
- Testing
- cognitive behavioral therapy, nondirective supportive therapy
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- Wake Forest University Health Sciences
Generalized Anxiety Disorder
Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults.
The purpose of this study is to evaluate the efficacy and safety of vortioxetine, once daily (QD), in adults with Generalized Anxiety Disorders.
- Trial name
- NCT00744627
- Testing
- Vortioxetine
- Where
- 38 sites in Estonia, Germany and 6 more
- Volunteers
- 301 people
- Sponsor
- Takeda
Autism, Asperger's Syndrome
Exposure-Focused Family-Based CBT for Youth With ASD and Comorbid Anxiety
Autism spectrum disorders affect as many as 1 out of 88 children and are related to significant impairment in social, adaptive, and school functioning.
- Conditions
- Autism, Asperger's Syndrome, Pervasive Developmental Disorder Not Otherwise Specified, Generalized Anxiety Disorder
- Trial name
- NCT01919970
- Testing
- Cognitive Behavioral Therapy, Treatment as usual
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University of South Florida
Generalized Anxiety Disorder
An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder
The purpose of this study is to determine the safety and efficacy of vortioxetine, once daily (QD), in treating Generalized Anxiety Disorder.
- Trial name
- NCT00734071
- Testing
- Vortioxetine
- Where
- 33 sites in United States
- Volunteers
- 304 people
- Sponsor
- Takeda
Anxiety, Obsessive-Compulsive Disorder
Virtual Reality System for Anxiety and OCD
Cognitive Behavioral Therapy with fear provoking exposures is the most effective therapy for anxiety disorders. The investigators aim to enhance this therapy with the use of virtual reality exposures.
- Trial name
- NCT03636022
- Testing
- VR System, Control
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Minnesota HealthSolutions
Generalized Anxiety Disorder
Duloxetine for the Treatment of Generalized Anxiety Disorder
This is a 15 week study comparing how well duloxetine and placebo treatments improve generalized anxiety disorder
- Trial name
- NCT00803361
- Testing
- Duloxetine
- Where
- 7 sites in China
- Volunteers
- 210 people
- Sponsor
- Eli Lilly and Company
Generalized Anxiety Disorder
Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use.
GAD subjects maintained on a stable dose of alprazolam for at least four weeks who meet eligibility criteria will be randomized to receive pregabalin vs matching placebo while simultaneously tapering off of alprazolam over 6…
- Trial name
- GAD (NCT00368745)
- Testing
- Pregabalin
- Where
- 21 sites in Costa Rica, Czechia and 5 more
- Volunteers
- 108 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Obsessive-Compulsive Disorder in Children, Social Anxiety Disorder of Childhood
Parent-based Treatment for Youth With Anxiety and Obsessive-compulsive Disorder
Anxiety and obsessive-compulsive disorders are the most common mental health disorders in childhood and adolescence. A parenting intervention for youth with anxiety, called Supportive Parenting of Anxious Childhood Emotions…
- Conditions
- Obsessive-Compulsive Disorder in Children, Social Anxiety Disorder of Childhood, Obsessive-Compulsive Disorder in Adolescence, Separation Anxiety
- Trial name
- NCT04922502
- Testing
- Standard SPACE, Bibliotherapy, low therapist contact SPACE
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Generalized Anxiety Disorder, Bipolar Disorder
Ziprasidone for the Treatment of Generalized Anxiety in Patients With Bipolar Disorder
This study proposes to examine the potential safety and efficacy of ziprasidone for patients with anxiety and bipolar disorder on anxiety outcomes, bipolar symptoms, and on measures of quality of life and resilience.
- Trial name
- NCT00374543
- Testing
- Ziprasidone
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Massachusetts General Hospital
Anxiety Disorders Generalized
A Pilot fMRI Study of TMS in Late-Life Severe Worry
Investigators will test a novel intervention through experimental therapeutic approach using fMRI-directed Intermittent Theta Burst Stimulation (iTBS), a high frequency TMS paradigm, for the treatment of severe, uncontrollable…
- Trial name
- TINA (NCT03577106)
- Testing
- Transcranial magnetic stimulation (TMS)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Carmen Andreescu
Obsessive-Compulsive Disorder, Generalized Anxiety Disorder
Memantine Treatment for Obsessive-compulsive Disorder and Generalized Anxiety Disorder
The objective of this study was to obtain preliminary open-label data on the efficacy and tolerability of memantine, an anti-glutamatergic medication with a unique pharmacodynamic profile, in individuals with OCD and individuals…
- Trial name
- NCT00674219
- Testing
- Memantine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of California, Los Angeles
Generalized Anxiety Disorder
Approach-Avoidance Conflict-a Multi-level Predictor for Therapy Response
This project aims to identify brain and behavioral characteristics of individuals experiencing symptoms of generalized anxiety disorder that will predict the effectiveness of Exposure-based therapy versus Behavioral Activation…
- Trial name
- NCT02807480
- Testing
- Exposure-based therapy, Behavioral Activation therapy, Computer-based behavioral assessment
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Laureate Institute for Brain Research, Inc.
Generalized Anxiety Disorder (GAD)
EDG004 Treatment of Adult Patients With Generalized Anxiety Disorder (GAD)
To evaluate the efficacy of EDG004 compared to placebo for the treatment of adult patients with GAD, diagnosed by Diagnostic and Statistical Manual of Mental Disorders, 5th Ed.
- Trial name
- NCT02305797
- Testing
- Extended-release lorazepam
- Where
- United States
- Volunteers
- 495 people
- Sponsor
- Edgemont Pharmaceuticals, LLC